DermBiont, a clinical-stage biotechnology company that is advancing first-in-class topical therapeutics to address patient needs in rare disease oncology and aesthetic dermatology, today announced positive initial data from its ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC).
Read MoreDermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics to address patient needs in three of the most frequently diagnosed dermatological indications, today announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024.
Read MoreDermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes. Proceeds will be used to advance two drugs in development, SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin.
Read MoreDermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced positive data from its Phase 2 trial with 0.8% SM-030 gel, a product under development capable of regulating pigmentation by controlling the formation of new melanin.
Read MoreDermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of a variety of dermatological indications, today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.
Read MoreDermBiont, a clinical-stage biotechnology company announced today positive results meeting primary and secondary endpoints in a Phase 2 clinical trial with a topical formulation of investigational drug SM-020, a specific and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK).
Read MoreDermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production. As part of the transaction, Jeni Lee, Principal at Pivotal Life Sciences, joins DermBiont’s Board of Directors. In addition to Pivotal Life Sciences, the round also includes participation from Viking Global Investors, Olive Tree Capital, Toba Capital, Civilization Ventures, and other biotechnology investors.
Read More
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. SeylanMED’s lead drug candidate, a topical AKT inhibitor gel, has the potential to be the first patient-applied treatment for seborrheic keratosis.
Read More